The gap between Allianz’s operational reality and its share price performance has rarely looked wider. Europe’s largest insurer reported a second-quarter net profit that missed expectations, yet its stock continues to hover within a whisker of record territory — a divergence that has left analysts scrambling to recalibrate their price targets.
The numbers tell a two-sided story. Net income fell 8.7 percent year-on-year to €2.6 billion, weighed down by €643 million in restructuring charges tied to IT modernization and preparations for a broader rollout of artificial intelligence across the group. That stands in stark contrast to the operating result of €4.9 billion — a record for the quarter — which nonetheless came in below consensus expectations, according to market participants.
A Stock That Refuses to Budge
Despite the earnings dip, the share price has shown remarkable resilience. At €441.00, the stock sits just 0.6 percent below its 52-week high of €443.80, a level first touched in early August. The secondary article notes the shares closed at €437.40 on Thursday, roughly 1.4 percent off that peak, with the relative strength index at 66.2 — a zone that suggests momentum is cooling but has not yet tipped into overbought territory. Since the start of the year, the stock has gained 13 percent, and it currently trades 14 percent above its 200-day moving average.
The market’s calm demeanor belies a flurry of activity beneath the surface. Management reaffirmed its full-year guidance of €17.4 billion in operating profit (plus or minus €1 billion), signaling confidence that it can land in the upper half of that range. Whether that ambition holds will depend on whether further one-off charges materialize in the second half — a risk that some analysts are reluctant to dismiss.
A Flurry of Analyst Moves
The post-earnings reaction from the sell-side has been anything but uniform. Jefferies held its Hold rating with a €325 price target on August 6, while RBC Capital Markets maintained its Sector Perform stance the same day with a €440 target. The DZ Bank struck a more bullish chord, lifting its fair value to €486 and reiterating a Buy recommendation on the day of the results.
The picture shifted further in the days that followed. Goldman Sachs raised its price target from €450 to €465 on Thursday, keeping a Buy rating — analyst Andrew Baker pointed to the strength of the second-quarter operating metrics as justification. Berenberg, for its part, reaffirmed a Buy on Monday, citing expected earnings growth from AI adoption and sustained inflows into the asset management business. RBC also nudged its target and forecasts higher on Monday, acknowledging that the quarter and recent acquisitions had proven more durable than initially feared.
The most aggressive call comes from Berenberg’s Michael Huttner, who on August 10 floated a €684 price target based on a sector re-rating through 2028 — a figure that underscores just how wide the dispersion of opinion has become.
Should investors sell immediately? Or is it worth buying Allianz?
Capital Returns and Strategic Moves
Behind the analyst debate lies a company deploying capital on multiple fronts. The buyback program, launched March 13, has seen the insurer repurchase 4,715,099 shares through July 31, including 234,428 in the final week of that month alone. The program allows for up to €2.5 billion in repurchases, with €1.4 billion already deployed by the end of June.
The balance sheet remains sturdy enough to support these moves. The Solvency II ratio stood at 225 percent as of June 30, seven percentage points above year-end 2025 levels. That financial headroom also underpins the planned acquisition of UOB Asset Management from Singapore’s United Overseas Bank for roughly 555 million Singapore dollars (about US$434 million) — a deal that extends Allianz Global Investors’ footprint in Asia. The insurer has also committed at least €1.4 billion to buy out the remaining 9.4 percent stake in Pimco held by employees.
The Bull and Bear Case in One Chart
For optimists, the combination of record operating results, a fortified capital position, and a steady stream of strategic initiatives provides ample justification for further price target upgrades. The management’s stated ambition to finish in the upper half of its guidance range, if realized, would likely trigger another round of upward revisions.
The skeptics counter that the stock has already run a long way — it sits 30 percent above its 52-week low from March 9 and carries a 5.3 percent premium to its 50-day average. RBC’s decision to keep a Neutral rating even while raising its target suggests that not everyone sees the same upside. The restructuring charges, meanwhile, could prove to be the first of several such hits if the company continues to reshape its cost base.
A separate reputational wrinkle emerged from a BaFin warning about a fraudulent website misusing the name of an Allianz fund — a matter unlikely to have operational consequences but one that adds a layer of noise to the investment case.
What Comes Next
The third quarter will serve as the first real test of whether the August guidance holds. If the upper half of the profit range comes into view and no fresh special charges emerge, the path for further moderate target hikes appears open — Goldman’s move this week is evidence that this channel remains active. A deterioration in earnings momentum, by contrast, would hand the advantage to the more cautious voices and could pull the stock back toward the more conservative price targets.
For now, the market seems content to give management the benefit of the doubt. The question is how long that patience lasts if the gap between operational drag and share price strength continues to widen.
Ad
Allianz Stock: Buy or Sell?! New Allianz Analysis from August 14 delivers the answer:
The latest Allianz figures speak for themselves: Urgent action needed for Allianz investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 14.
Allianz: Buy or sell? Read more here...
